Adherence to statins and the risk of psoriasis: A population-based cohort study

British Journal of Dermatology

Volumn 173, Issue 2, 2015, Pages 480-487

  Chodick, G ^a,b   Weitzman, D ^a,c   Shalev, V ^a,b   Weil, C ^a   Amital, H ^c,d  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; ISRAEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT OUTCOME; AGED; AGEISM; RISK FACTOR; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGED; AGEISM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; ISRAEL; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84941081444     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13850     Document Type: Article

References (40)

1. Gelfand JM, Stern RS, Nijsten T, et al,. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005; 52: 23-6.
2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
3. Choi WJ, Park EJ, Kwon IH, et al,. Association between psoriasis and cardiovascular risk factors in Korean patients. Ann Dermatol 2010; 22: 300-6.
4. Kaye JA, Li L, Jick SS,. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
5. Dowlatshahi E, Voort E, Arends L, Nijsten T,. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2013; 169: 266-82.
6. Ghazizadeh R, Tosa M, Ghazizadeh M,. Clinical improvement in psoriasis with treatment of associated hyperlipidemia. Am J Med Sci 2011; 341: 394-8.
7. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al,. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
8. Coward W, Chow S,. Effect of atorvastatin on TH1 and TH2 cytokine secreting cells during T cell activation and differentiation. Atherosclerosis 2006; 186: 320-9.
9. Wolkenstein P, Revuz J, Roujeau JC, et al,. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology 2009; 218: 103-9.
10. Brauchli YB, Jick SS, Meier CR,. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol 2011; 65: 77-83.
11. Faghihi T, Radfar M, Mehrabian Z, et al,. Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy 2011; 31: 1045-50.
12. Shirinsky I, Shirinsky V,. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol 2007; 57: 529-31.
13. Naseri M, Hadipour A, Sepaskhah M, Namazi M,. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med 2010; 19: 58-61.
14. Shapiro J, Cohen AD, David M, et al,. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629-34.
15. Peterson AM, Nau DP, Cramer JA, et al,. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12.
16. Valuck RJ, Williams SA, MacArthur M, et al,. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003; 25: 2936-57.
17. Meyer JW, Schultz JS, O'Donnell JC, et al,. Patterns and effectiveness of lipid-lowering therapies in a managed care environment. Value Health 2005; 8: 601-12.
18. Jones P, Kafonek S, Laurora I, Hunninghake D,. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-7.
19. Dujovne CA, Knopp R, Kwiterovich P, et al,. Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group. Mayo Clin Proc 2000; 75: 1124-32.
20. Cheng JW,. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004; 26: 1368-87.
21. Chodick G, Heymann AD, Shalev V, Kookia E,. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 2003; 18: 1143-6.
22. Coumbe AG, Pritzker MR, Duprez DA,. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med 2014; 127: 12-18.
23. Grambsch P, Therneau T,. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-26.
24. Henseler T, Christophers E,. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-6.
25. Rosenbaum PR, Rubin DB,. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
26. Imbens GW,. The role of the propensity score in estimating dose response functions. Biometrika 2000; 87: 706-10.
27. Strandberg T, Pyörälä K, Cook T, et al,. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364: 771-7.
28. Icen M, Crowson CS, McEvoy MT, et al,. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009; 60: 394-401.
29. Huerta C, Rivero E, Rodriguez LA,. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-65.
30. Martínez-Borra J, Brautbar C, González S, et al,. The region of 150 kb telometic to HLA-C is associated with psoriasis in the Jewish population. J Invest Dermatol 2005; 125: 928-32.
31. Roitberg-Tambur A, Friedmann A, Tzfoni EE, et al,. Do specific pockets of HLA-C molecules predispose Jewish patients to psoriasis vulgaris? J Am Acad Dermatol 1994; 31: 964-8.
32. Mittal R, Malhotra S, Pandhi P, et al,. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009; 145: 387-93.
33. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
34. Rucevic I, Perl A, Barisic-Drusko V, Adam-Perl M,. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol 2003; 27 (Suppl. 1): 41-8.
35. Mann DM, Allegrante JP, Natarajan S, et al,. Dietary indiscretion and statin use. Mayo Clin Proc 2007; 82: 951-7.
36. Shalev V, Goldshtein I, Halpern Y, Chodick G,. Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings. Pharmacotherapy 2014; 34: 1-8.
37. Li Wan Po A,. Dictionary of Evidence-based Medicine. Oxford: Radcliffe Medical Press, 1998.
38. Chodick G, Amital H, Shalem Y, et al,. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 2010; 7: e1000336.
39. Chodick G, Shalev V, Gerber Y, et al,. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167-79.
40. Herron MD, Hinckley M, Hoffman MS, et al,. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-34.